Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

18.70 -0.46 (-2.40%)

Delayed Quote Updated: 2:34 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Denali Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023 ↗

September 06, 2023

Via Benzinga

Analyst Expectations for Denali Therapeutics's Future ↗

August 31, 2023

Via Benzinga

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

August 30, 2023

From Denali Therapeutics Inc.

Via GlobeNewswire

Where Denali Therapeutics Stands With Analysts ↗

August 10, 2023

Via Benzinga

Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

August 08, 2023

From Denali Therapeutics Inc.

Via GlobeNewswire

Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now ↗

June 29, 2023

With longevity back in the news, many investors are wondering which biotech stocks to buy to best cash in on the growing trend.

Via InvestorPlace

Analyst Expectations for Denali Therapeutics's Future ↗

June 21, 2023

Within the last quarter, Denali Therapeutics (NASDAQ:DNLI) has observed the following analyst ratings:

Via Benzinga

Denali Says Hunter Syndrome Candidate Lowers Disease-Associated Biomarker ↗

June 20, 2023

Denali Therapeutics Inc (NASDAQ: DNLI) announced new interim results from the ongoing open-label, single-arm Phase 1/2 study of DNL310 IDS in children with

Via Benzinga

Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)

June 20, 2023

From Denali Therapeutics Inc.

Via GlobeNewswire

Why Shares of Denali Therapeutics Are Up Monday ↗

May 15, 2023

Analysts maintained their buy ratings on the clinical-stage biotech company.

Via The Motley Fool

Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure ↗

June 05, 2023

Via Benzinga

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

May 18, 2023

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

Via MarketBeat

Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 08, 2023

From Denali Therapeutics Inc.

Via GlobeNewswire

Biogen Moves Deeper In Alzheimer's With Denali ↗

April 14, 2023

Biogen exercised their rights to a Denali Alzheimer's drug. What does this mean longer term to the field and the companies?

Via Talk Markets

Where Denali Therapeutics Stands With Analysts ↗

April 12, 2023

Via Benzinga

Where Denali Therapeutics Stands With Analysts ↗

March 02, 2023

Via Benzinga

Expert Ratings for Denali Therapeutics ↗

January 30, 2023

Via Benzinga

Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta

April 12, 2023

Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting

April 10, 2023

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

February 27, 2023

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Reveals New Interim Data From Early-Stage Hunter Syndrome Study ↗

February 23, 2023

Via Benzinga

Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™

February 22, 2023

From Denali Therapeutics Inc.

Via GlobeNewswire

3 More Mid-Cap Biotechs The Street Sees Doubling

February 22, 2023

According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk.

Via MarketBeat

Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™

February 15, 2023

From Denali Therapeutics Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023 ↗

January 30, 2023

Via Benzinga

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi

January 25, 2023

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases

January 09, 2023

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial

December 05, 2022

From Denali Therapeutics Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022 ↗

December 05, 2022

Via Benzinga

Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

November 03, 2022

From Denali Therapeutics Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.